Pharma channel feed

Ok­la­homa over­turns his­toric opi­oid de­ci­sion against J&J, wip­ing out $465M fine

4 years ago

The very slow roll of Bio­gen's Aduhelm: Neu­rol­o­gists weigh in on pa­tients, prac­tices and pay­ments amid on­go­ing me­dia storm

4 years ago
Marketing

Mar­ket­ingRx roundup: J&J qui­et­ly launch­es a new 'World of Well' cor­po­rate cam­paign; Genen­tech spon­sors orig­i­nal song for SMA aware­ness

4 years ago
Marketing

Move over KOLs, there’s a new in­flu­encer in town. Meet the dig­i­tal opin­ion lead­ers tak­ing over on­line

4 years ago
Marketing

Q&A: From Aber­crom­bie to GSK, cus­tomer ex­pe­ri­ence ex­pert Andy Ken­nemer on his fash­ion-for­ward leap to phar­ma

4 years ago
Marketing

Ac­cel­er­at­ed ap­provals un­der fire again as piv­otal tri­als typ­i­cal­ly take about as long as con­fir­ma­to­ry tri­als, re­search shows

4 years ago
FDA+

Look­ing to get ahead in a packed mi­graine mar­ket, Am­gen touts head-to-head da­ta for Aimovig

4 years ago
R&D
Marketing

Bio­gen in­ves­ti­gates a death pos­si­bly linked to its con­tro­ver­sial new Alzheimer's drug

4 years ago

Bris­tol My­ers adds to neoad­ju­vant win for Op­di­vo in lung can­cer, es­ca­lat­ing ear­ly can­cer show­down with Mer­ck

4 years ago
R&D

A Bloomberg-backed can­cer drug sum­mit aims to thaw US-Chi­na re­la­tions

4 years ago
China

Ab­bott plots new paths to clin­i­cal tri­al di­ver­si­ty, join­ing bio­phar­ma push for broad­er in­clu­sion

4 years ago
Marketing

Seagen and Dai­ichi are duk­ing it out over the link­ers used in some block­buster drug plays. Could that af­fect a high-dol­lar As­traZeneca col­lab­o­ra­tion?

4 years ago

Mixed court de­ci­sions for No­var­tis in DC and Sanofi, No­vo Nordisk in NJ fur­ther com­pli­cate whose in­ter­pre­ta­tion of 340B is cor­rect

4 years ago
R&D

House Over­sight Com­mit­tee digs in on McK­in­sey's con­flict­ing ties with FDA, opi­oids, and block­ing Hu­mi­ra com­peti­tors

4 years ago
FDA+

Dem­s' $100B deal re­duced fur­ther: Medicare drug price ne­go­ti­a­tions pushed to 13 years for bi­o­log­ics

4 years ago
FDA+

Thanks for the boost, biotech. Phar­ma in­dus­try rep­u­ta­tion now close to biotech in­dus­try es­teem: Har­ris Poll

4 years ago
Marketing

As gen­er­a­tion gaps nar­row from boomers down to Gen Z, phar­ma needs to re­con­sid­er me­dia, re­searcher says

4 years ago
Marketing

Dems forge lim­it­ed agree­ment on Medicare drug price ne­go­ti­a­tions

4 years ago
FDA+

In­tro­duc­ing Mar­ket­ingRx and why phar­ma mar­ket­ing mat­ters. Pay at­ten­tion biotechs, it’s not just for Big Phar­ma any­more

4 years ago
Marketing

Q&A: Mod­er­na’s chief brand of­fi­cer on nav­i­gat­ing the Covid-19 spot­light and chart­ing the biotech brand’s fu­ture

4 years ago
Marketing

Mar­ket­ingRx roundup: J&J boosts health eq­ui­ty goals in 6-city chal­lenge; Al­ler­gan Aes­thet­ics kicks off breast can­cer ef­forts

4 years ago
Marketing

Pfiz­er re­veals de­lays across the board for its clin­i­cal gene ther­a­py pro­grams

4 years ago

Dems res­ur­rect a scaled back plan for Medicare drug price ne­go­ti­a­tions

4 years ago
R&D

Cal­i­for­nia judge sides with drug­mak­ers in $50B opi­oid law­suit

4 years ago
First page Previous page 233234235236237238239 Next page Last page
A service from the Financial Times